促肾上腺皮质激素刺激试验无反应是否提示脓毒性休克中的糖皮质激素抵抗?
该研究比较两种氢化可的松方案在脓毒性休克患者中的效果,并按促肾上腺皮质激素刺激试验(CST)反应分层分析。200 mg组(n=49)为50 mg静脉推注每6小时一次、持续7天;300 mg组(n=50)为首剂100 mg推注后每日持续输注300 mg、持续5天。无反应定义为CST反应≤9 μg/dL。无反应者脓毒性休克更重、液体复苏需求更大、血管活性药物依赖更强。仅按CST结果分析时,反应者与无反应者生存无差异;但交叉分析显示,反应者中300 mg组ICU死亡率显著低于200 mg组(24% vs 55%,相对风险0.43,95%CI 0.20–0.94,P=0.018)。多因素分析显示基线血皮质醇为28天死亡率独立预后因素(HR 1.002,95%CI 1.001–1.002,P≤0.0001)。结果提示对CST有反应者氢化可的松可能提供剂量依赖性获益,无反应可能提示糖皮质激素抵抗。
要点
- 脓毒性休克患者中,CST反应者使用氢化可的松300 mg/d方案较200 mg/d方案ICU死亡率更低(24% vs 55%,RR 0.43,95%CI 0.20–0.94,P=0.018)。
- CST无反应定义为反应≤9 μg/dL;无反应者脓毒性休克更重、液体复苏需求更大、血管活性药物依赖更强。
- 仅按CST结果分层时,反应者与无反应者生存无差异。
- 基线血皮质醇是全组28天死亡率独立预后因素(HR 1.002,95%CI 1.001–1.002,P≤0.0001)。
- 作者认为无反应可能提示糖皮质激素抵抗,可解释氢化可的松在脓毒性休克中获益难以显现的异质性。
适用人群与场景
- 脓毒性休克患者,纳入两项氢化可的松剂量方案比较:200 mg组(n=49)与300 mg组(n=50)。
诊断标准与关键阈值
- CST无反应定义为促肾上腺皮质激素刺激试验反应≤9 μg/dL。
处置流程与药物剂量
- 200 mg组:氢化可的松50 mg静脉推注,每6小时一次,持续7天。
- 300 mg组:氢化可的松首剂100 mg静脉推注,随后每日持续输注300 mg,持续5天。
研究设计与关键结果
- 研究比较两种氢化可的松方案在脓毒性休克患者中的效果,并按CST反应分层:200 mg组n=49,300 mg组n=50。
- 无反应者较反应者脓毒性休克更重、液体复苏需求更大、血管活性药物依赖更强。
- 仅按CST结果分析,反应者与无反应者生存无差异。
- 交叉分析显示,反应者中300 mg组较200 mg组ICU死亡率显著降低(24% vs 55%,RR 0.43,95%CI 0.20–0.94,P=0.018)。
- 多因素分析显示基线血皮质醇为全组28天死亡率独立预后因素(HR 1.002,95%CI 1.001–1.002,P≤0.0001)。
证据类型、等级与局限
- 证据类型:基于已发表的两组氢化可的松剂量方案比较的二次分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,对CST有反应的脓毒性休克患者,氢化可的松可能提供剂量依赖性获益。
- 作者认为,CST无反应可能提示糖皮质激素抵抗,此异质性可能解释氢化可的松在脓毒性休克中获益难以显现的原因。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
We recently published a comparison of two hydrocortisone dosage regimens in patients with septic shock. We compare the results conferred by the two regimens as a function of the response to cosyntropin stimulation test (CST). Patients with septic shock were treated by one of two hydrocortisone regimens: either a 50-mg intravenous bolus every 6 h during 7 days (200 mg group; n = 49), or a 100-mg initial bolus followed by a continuous infusion of 300 mg daily for 5 days (300 mg group; n = 50). Nonresponders was defined as a CST response of 9 μg/dL or less. Nonresponders had more severe septic shock, greater fluid resuscitation needs, and greater vasopressor dependence than responders. When analyzed only as a function of CST results, there was no difference in survival between responders and nonresponders. However, analyses crossing CST results and the treatment regimens showed that patients who were responders and in the 300 mg group had significantly less intensive care unit mortality compared with responders in the 200 mg group (respective mortality of 24% vs. 55% [relative risk 0.43, 95% confidence interval, 0.20 to 0.94, P = 0.018]). Multivariate analysis identified baseline blood cortisol as an independent prognostic factor for 28-day mortality in all groups (hazard ratio 1.002, 95% confidence interval, 1.001 to 1.002, P ≤ 0.0001). The results suggest that in patients who respond to CST, hydrocortisone can provide a dose-dependent benefit. In contrast, nonresponse may indicate corticosteroid resistance. This heterogeneity of response to hydrocortisone may explain the difficulties encountered when trying to demonstrate its benefit in septic shock.
参考来源
- Hyvernat H, Doyen D, Barel R, et al. Is Inappropriate Response to Cosyntropin Stimulation Test an Indication of Corticosteroid Resistance in Septic Shock? Shock. 2018. PMID: 28991048. doi:10.1097/SHK.0000000000001014
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。